Opus Genetics Past Earnings Performance

Past criteria checks 0/6

Opus Genetics has been growing earnings at an average annual rate of 21.5%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 60.2% per year.

Key information

21.5%

Earnings growth rate

43.7%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate60.2%
Return on equity-79.3%
Net Margin-324.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Opus Genetics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:R3X1 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 248-27140
30 Jun 2416-14131
31 Mar 2419-11140
31 Dec 2319-10120
30 Sep 235729111
30 Jun 2345191010
31 Mar 23421980
31 Dec 22401870
30 Sep 220-2270
30 Jun 220-2270
31 Mar 221-2480
31 Dec 211-5780
30 Sep 211-6980
30 Jun 210-6670
31 Mar 210-6140
31 Dec 200-2530
30 Sep 200-821
30 Jun 200-922
31 Mar 200-822
31 Dec 190-622

Quality Earnings: R3X1 is currently unprofitable.

Growing Profit Margin: R3X1 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: R3X1 is unprofitable, but has reduced losses over the past 5 years at a rate of 21.5% per year.

Accelerating Growth: Unable to compare R3X1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: R3X1 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.4%).


Return on Equity

High ROE: R3X1 has a negative Return on Equity (-79.28%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 18:11
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Opus Genetics, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
John NewmanCanaccord Genuity
Kristen KluskaCantor Fitzgerald & Co.